Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Malcolm RansonGeoffrey P Margison

Abstract

A major mechanism of resistance to temozolomide involves the DNA repair protein O6-alkylguanine-DNA-alkyltransferase (ATase). The main aims of this phase I trial were to determine an ATase-depleting dose (ADD) of lomeguatrib, a potent pseudosubstrate inhibitor, and to define a suitable dose of temozolomide to be used in combination with lomeguatrib in patients with advanced cancer. Lomeguatrib was administered at dose levels of 10 to 40 mg/m2 days 1 to 5, as a single agent, and also in combination with temozolomide. Once the ADD of lomeguatrib was identified, the dose of temozolomide in combination was increased, in successive patient cohorts, from 50 to 175 mg/m2 on days 1 to 5 of a 28-day cycle to define the maximal tolerated dose and dose-limiting toxicity of the combination. Thirty-eight patients with advanced solid tumors were enrolled. More than 95% ATase depletion within 4 hours of the first dose was achieved in peripheral blood mononuclear cells at lomeguatrib doses of > or =10 mg/m2/d i.v. or > or =20 mg/m2/d orally, and tumor biopsies showed > or =92% ATase depletion. At the ADD of lomeguatrib i.v., the maximal tolerated dose of temozolomide in combination was 150 mg/m2 days 1 to 5. The dose limiting toxicity of the c...Continue Reading

References

Sep 1, 1992·Carcinogenesis·J M ChenM Ikenaga
Feb 19, 1992·Journal of the National Cancer Institute·K C MicetichL C Erickson
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S FriedmanM E Dolan
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer A QuinnHenry S Friedman
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stanton L Gerson
Jul 19, 2002·International Journal of Cancer. Journal International Du Cancer·Mark R MiddletonGeoffrey P Margison
Jan 9, 2003·The Lancet Oncology·Mark R Middleton, Geoffrey P Margison
May 29, 2003·Mini Reviews in Medicinal Chemistry·R S McElhinneyG P Margison
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J van den BentUNKNOWN European Organization for Research and Treatment of Cancer Brain Tumor Group
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S DansonM R Middleton

❮ Previous
Next ❯

Citations

Mar 3, 2007·Cancer Chemotherapy and Pharmacology·Stewart P JohnsonHenry S Friedman
Jun 23, 2009·Cancer Chemotherapy and Pharmacology·J Lee VillanoLinda R Bressler
Sep 4, 2009·Cancer Chemotherapy and Pharmacology·Holger Peter BehrsingRalph E Parchment
Dec 30, 2009·Cancer Chemotherapy and Pharmacology·A SabharwalM R Middleton
Mar 23, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Mehmet TaspinarHasan Caglar Ugur
Sep 8, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Nicholas J HawkinsMegan P Hitchins
Jun 11, 2008·Nature Clinical Practice. Oncology·Maciej M Mrugala, Marc C Chamberlain
Feb 8, 2008·Nature Reviews. Cancer·Thomas HelledayRicky A Sharma
Nov 24, 2012·Nature Reviews. Cancer·Nicola J Curtin
Dec 2, 2006·The Journal of Biological Chemistry·Joseph J RasimasMichael G Fried
Dec 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ruth PlummerHilary Calvert
Jan 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amanda J WatsonMark R Middleton
Feb 9, 2008·Pharmacology·Howard R Mellor, Richard Callaghan
Aug 19, 2010·Cellular and Molecular Life Sciences : CMLS·Bernd KainaMarkus Christmann
May 17, 2007·Expert Opinion on Therapeutic Targets·Nicola Curtin
Apr 3, 2013·Expert Review of Neurotherapeutics·Brian M AlexanderPatrick Y Wen
Oct 10, 2007·Expert Opinion on Investigational Drugs·Omar Khan, Mark R Middleton
Apr 24, 2013·Clinics in Dermatology·Jason J Luke, Gary K Schwartz
Jul 24, 2012·Cancer Treatment Reviews·Zuzana TatarXavier Durando
Nov 13, 2007·Biochemical Pharmacology·Qingming FangAnthony E Pegg
Jun 5, 2013·Pharmaceutical Statistics·Nolan A Wages, Mark R Conaway
May 21, 2013·British Journal of Pharmacology·N J Curtin
Jul 19, 2012·Statistics in Medicine·Nolan A WagesJohn O'Quigley
Dec 18, 2007·Seminars in Oncology·Hussein A Tawbi, John M Kirkwood
Sep 18, 2015·Molecular Pharmaceutics·Karl-Heinz TomaszowskiBernd Kaina
Feb 16, 2011·Bioorganic & Medicinal Chemistry·Sergio LopezIsabel Rozas
Mar 8, 2014·Clinical Oncology : a Journal of the Royal College of Radiologists·R Plummer
Apr 11, 2009·Journal of Molecular Biology·Claire A AdamsMichael G Fried
Aug 21, 2016·Mutation Research. Reviews in Mutation Research·Hélène ErasimusEric Van Dyck

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.